Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, retaining the price target of CHF6.00.

Ram Selvaraju has given his Buy rating due to a combination of factors related to Idorsia’s lucerastat program and Fabry disease market dynamics. He highlights that Idorsia has now secured FDA alignment on a clear, streamlined Phase 3 registration pathway for lucerastat, centered on robust renal endpoints that directly address key drivers of Fabry disease morbidity and mortality.

He also underscores that lucerastat’s planned positioning as an oral therapy suitable for essentially all Fabry patients, regardless of mutation type, could allow it to target a substantially larger population than existing molecular chaperones, which are limited to “amenable” variants. Coupled with a Fabry market projected to expand toward several billion dollars over the coming decade and a defined timeline to potential regulatory filing around 2029, Selvaraju views the risk‑reward profile as favorable, supporting his Buy rating and CHF6 twelve‑month price target.

In another report released on January 28, Kepler Capital also maintained a Buy rating on the stock with a CHF4.50 price target.